Articles related to GENETICS

The 2024 HCM guideline introduces cardiac myosin inhibitors as a new therapeutic option and relaxes exercise restrictions, potentially altering the landscape of HCM management.

This study reveals that individuals with autosomal dominant Alzheimer’s disease who are heterozygous for the APOE3 Christchurch variant experience a median delay in cognitive impairment onset of approximately five years compared to those without the variant.

A phase 3 trial demonstrates that aficamten improves oxygen utilization during exercise for obstructive HCM patients, indicating its potential to enhance daily functionality and quality of life.

Recent systematic reviews suggest a subtle increase in NMOSD and MS risks post-COVID-19 vaccination, primarily affecting genetically susceptible individuals.

Recent research from Brown University suggests that the SARS-CoV-2 spike protein could interfere with cancer treatment efficacy by affecting the p53 gene’s ability to suppress tumor growth and repair DNA.

Deep within the diagnostic labyrinth lies a pivotal clue: the presence of ragged-red fibers and COX-deficient fibers on muscle biopsy, unveiling a hidden mitochondrial cytopathy underlying neurological dysfunction.